ALYSSON GAINES: Open Payments
NPI 1437655065 · BENTONVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 48 payments from 16 companies in 2025. Trend: 2023 $372 · 2024 $169 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $245 |
| Novo Nordisk Inc | 7 | $239 |
| ABBVIE INC. | 10 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $77 |
| GlaxoSmithKline, LLC. | 3 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $51 |
| Dexcom, Inc. | 2 | $43 |
| Corium, LLC | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
Products named: Ozempic, BREZTRI, QULIPTA, CAPLYTA, AIRSUPRA, TRELEGY ELLIPTA, Wegovy, Kerendia.
Industry payments across AR — which companies pay providers there.
